CREATION Pinpoint’s Drug Launch Tracker shows how healthcare professionals (HCPs) respond to drug launch news, as it happens. The FDA approved over 400 submissions between 11 February 2020 – 10 March 2020, which included medications that are used to treat epilepsy and neuropathic pain, bacterial infections and adults with Cushing’s syndrome.
The most mentioned FDA approvals by HCPs online
|Brand||Compound(s)||Manufacturer||Brand mentions||Compound mentions||Total mentions|
|Nexletol||bempedoic||Esperion Therapeutics Inc||10||51||61|
|Nurtec||rimegepant||Biohaven Pharma Holding Co Ltd||21||34||55|
|Isturisa||osilodrostat||Novartis Pharms Corp||12||16||28|
|Nexlizet||bempedoic acid;ezetimibe||Esperion Therapeutics Inc||2||24||26|
|Vyeptibla||eptinezumab-jjmr||Lundbeck Seattle Biopharmaceuticals, Inc.||0||23||23|
|Trulicitybla||dulaglutide||Eli Lilly And Co||0||20||20|
|Voltaren||diclofenac sodium||Glaxosmithkline Cons||18||0||18|
|Anjeso||meloxicam||Baudax Bio Inc||9||0||9|
|Barhemsys||amisulpride||Acacia Pharma Ltd||3||5||8|
|Twirl||levonorgestrel;ethinyl estradiol||Agile Therapeutics Inc||7||0||7|
|Albuterol||albuterol sulfate||Perrigo Pharms Co||6||0||6|
|Advil||ibuprofen; acetaminophen||Pfizer Inc||6||0||6|
|Apixaban||apixaban||Dr Reddys Labs Inc||5||0||5|
|Olopatadine||olopatadine hydrochloride||Watson Labs Inc||4||0||4|
|Sarclisabla||isatuximab-irfc||Sanofi Aventis Us||0||3||3|
|Metformin||metformin hydrochloride||Saptalis Pharms||3||0||3|
|Nicotine||nicotine polacrilex||Dr Reddys Labs Sa||3||0||3|
|Ofev||nintedanib esylate||Boehringer Ingelheim||2||0||2|
|Suboxone||buprenorphine hydrochloride; naloxone hydrochloride||Indivior Inc||1||0||1|
|Procysbi||cysteamine bitartrate||Horizon Pharma Usa||1||0||1|
|Lenvim||lenvatinib mesylate||Eisai Inc||1||0||1|
|Nerlynx||neratinib maleate||Puma Biotech||1||0||1|
Espion’s Nexletol (bempedoic acid) was the most mentioned FDA approval by HCPs this month with 95 mentions. The news of the approval was greeted with HCPs sharing this news saying that it is the ‘first non-statin pill in two decades’ and ‘another tool in our arsenal’. A tweet by Michael Gibson, a US cardiologist, shared an article by STAT news stating that Nexletol could be used to test the market of heart medications. This test will see whether the price of the medication is a barrier in the market.
After 21-year journey, Esperion’s cholesterol lowering drug #Bempedoic acid is now FDA approved and will test market for a cholesterol pill that is less expensive by @matthewherper https://t.co/Us0CVA9LZk via @statnews
— C. Michael Gibson MD (@CMichaelGibson) February 21, 2020
The second most mentioned FDA approval by HCPs was Nurtec (rimegepant) with 55 mentions. HCPs were positive towards Nurtec saying that it is ‘pretty great to have options’ and ‘another great new weapon’. An article by the American Headache Society sharing the news of the approval and giving information about how Nurtec works was tweeted six times by HCPs.
The FDA approved rimegepant for the acute treatment of migraine in adults. This is the first calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT). Read more: https://t.co/TAQ5S5OiRt pic.twitter.com/OFivMSSK72
— American Headache Society (@ahsheadache) February 28, 2020
We are tracking the HCP reaction to FDA approvals and related topics each month. You can keep up to date with this and other pharmaceutical tracking updates within the Tracking section of CREATION Knowledge, or by signing up to our monthly eJournal.
READ LAST MONTH’S FDA APPROVAL TRACKER:
FDA Tracker: Novo Nordisk’s Ozempic and Rybelsus the most mentioned approvals
- Data for this research was analysed from the online Twitter conversations of HCPs talking about FDA approvals in English language (all other languages are available), between February 11th 2020 and March 10th 2020.
- Between February 11th 2020 and March 10th 2020, 1,291 HCPs shared posts about FDA approvals 1,713 times all over the world.
- The table refers only to approvals that occurred between February 11th 2020 and March 10th 2020. Mentions of approvals before February 11th were not included.
- HCPs mention brand and compound names when discussing FDA approvals. Approvals may include multiple brands and compounds.